Nutraceuticals from Microbes of Marine Sources by Gupta, Charu & Prakash, Dhan
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Nutraceuticals from Microbes of 
Marine Sources
Charu Gupta and Dhan Prakash
Abstract
Therapeutic compounds can be derived from various natural sources like plants, 
animals, marine organisms, and microorganisms. Although the marine biota 
accounts for around 50% of the total world biodiversity, but their potential as a 
rich source of bioactive products and their applications in both pharmaceutical and 
nutraceutical industries have only recently been identified through several scientific 
studies. Marine biotechnology is an upcoming area that involves about the study of 
marine microorganisms and animals including algae, sponges, and coral as a novel 
source of bioactive substances that can be used in the treatment of various human 
diseases like cancer, anemia, diarrhea, obesity, diabetes, atopic dermatitis, Crohn’s 
disease, etc. They are also potential sources of natural antioxidants, colors, immuno-
suppressants, enzyme inhibitors, hypocholesterolemic agents, vitamins, enzymes, 
and antibiotics. However, marine microorganisms have not yet been given the atten-
tion they deserve and a very limited scientific data is available on bioactive potential 
of marine microorganisms. There is still scope for a higher magnitude of research 
and investigation to explore the potential of both marine organisms and marine 
microorganisms as producers of novel drugs. This chapter deals with the exploita-
tion of microbes from marine sources as potential sources for various nutraceuticals 
and their possibilities for applications in variety of diseases and as functional food 
supplement.
Keywords: microbes, nutraceuticals, marine organisms, functional food, 
bioactive compounds
1. Introduction
It is well-known that more than 70% of our planet’s surface is covered by oceans. 
Experts estimate that the biological diversity in marine environment is higher than 
in tropical rain forests. Marine water contains enormous amounts of biodiversity 
which makes it as a source of huge amounts and wide varieties of novel bioactive 
compounds. The majority of the marine microbiota is soft bodied and follows a 
sedentary life style, thus requiring the other means of defense systems mainly by 
producing certain biochemical compounds that are generally toxic to the other ani-
mals. These toxic substances also aid them in detecting their harmful predators, and 
help them to protect themselves from their competitors or they can even paralyze 
their enemies. The biodiversity of marine microflora is overwhelming and there 
is an urgent need to explore and exploit their potential as biotherapeutic agents. 
These biotherapeutic compounds are usually synthesized as secondary metabolites 
by the marine microflora and fauna. The disadvantage is that since these natural 
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products are synthesized and released extracellularly into the water so they are 
rapidly diluted and, therefore, their potency should be very high to show any effect. 
It is well-known that a large number of novel bioactive natural compounds are 
found in the oceans, and deep sea possessing various biological properties that can 
be exploited for discovering various drugs with improved efficacy and action in the 
treatment of various human diseases like cancer, anemia, diarrhea, obesity, diabe-
tes, atopic dermatitis, Crohn’s disease, etc. [1, 2].
The oceans are the source of a large group of structurally unique natural 
products that are mainly accumulated in invertebrates such as sponges, tunicates, 
bryozoans, and mollusks.
Macroalgae (or seaweed) are one of the most well-known types of algae used 
in the production of various nutraceuticals or dietary supplements. They are a rich 
source of valuable bioactive substances with both therapeutic and preventative 
effect. They have been used to develop a great variety of food and food ingredients, 
especially in Asian countries including Korea, Japan, and China. It is estimated that 
China and Indonesia are by far the largest seaweed producers with over 23 million 
tons of aggregated production in 2014 [3]. About 2400 natural products have been 
isolated from macroalgae belonging to the classes Rhodophyceae, Phaeophyceae, 
and Chlorophyceae [4]. Presently, seaweeds constitute commercially important 
marine renewable resources which are providing valuable ideas for the development 
of new drugs against diabetes, microbial infections, and inflammations [5]. Algal 
constituents include acids, alkaloids, amines, antibacterial, antifungal, antiviral 
substances, lipids, sterols, steroids, fatty acids, phenolic compounds, phyto-
chromes, pigments, proteins, peptides, amino acids, sugar, alcohols, and vitamins. 
Gracilaria opuntia belongs to the family Rhodophyceae (Red algae) and possesses 
various biological activities.
The potential of marine microorganisms in producing various bioactive metabo-
lites is due to their unique biochemical and physicochemical properties inherited 
by them in order to survive in extreme environmental conditions in the marine 
environment. These unique bioactive “bioceuticals” have tremendous potential for 
use as active pharmaceutical ingredient (API) and in food supplements to design 
various nutraceuticals [6].
Most of the bioactive compounds are having numerous biological activities 
which are found to act as nutraceuticals for humans and animals. Thus, the marine 
microflora contributes an important source of various bioactive constituents. Due 
to the great diversity of the marine flora, the chemistry of its associated bioactive 
compounds is also novel [7]. The marine flora includes a wide range of organisms 
from sponges, tunicates, bryozoans, mollusks to bacteria, microalgae, macroalgae, 
and cyanobacteria. The bioactive metabolites produced as a result of their metabolic 
activity is therefore effective in treatment of both infectious and non-infectious 
diseases.
Marine microflora including algae are widely used in the development of vari-
ous nutraceuticals and are also used as food source or food ingredients [8]. Algae 
include both the micro- and macroforms and both the types are used as nutra-
ceuticals. Microalgae are the most primitive and simply organized algae present 
in marine environment. They are the rich sources of various food nutrients and 
vitamins such as beta-carotene (vitamin A), vitamin C, E, H, B1, B2, B6, and B12, 
astaxanthin, polysaccharides, and polyunsaturated fatty acids [9]. These bioac-
tive compounds are extracted from the microalgae and are used as food additives, 
fortifying infant milk, and other dietary supplements [10]. These compounds 
(especially the tunicate metabolite ET-743) have also shown good pharmacological 
properties and can be used to develop new drugs for cancer treatment. Some other 
compounds such as ziconotide obtained from the mollusk (Conus magus) are used 
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as analgesics and anti-inflammatory. Natural products localized in symbiotic bacte-
ria or cyanobacteria from marine invertebrates exhibits striking structural similari-
ties with the known microbial metabolites; suggesting that bacteria and microalgae 
are involved in their biosynthesis and are the true sources of these metabolites. 
Nowadays, molecular techniques are used to study the microbial diversity in marine 
sponges and to study the involvement of bacteria in the biosynthesis of the bryo-
statins in the bryozoan Bugula neritina [2].
2. Marine microorganisms as source of nutraceuticals
A study reported that some unidentified prokaryotic communities, such as the 
JS1 and DSAG groups, occur widely in organic rich deep marine sediments associ-
ated with methane hydrates along the Pacific Ocean margin. The microflora is 
present in deep marine sediments and their community structure is affected by the 
surrounding geochemical and geological settings. Various studies have shown that 
many classes of microorganisms exist only in the sea [11]. Thus, limited scientific 
data is available on the growth media and culture techniques for culturing these 
marine microbes.
Many pharmaceutical industries have not been able to fully utilize this impor-
tant resource. There is a general belief that marine microorganisms are difficult to 
culture; however, now there are a number of reports that showed that these marine 
microorganisms can be successfully cultured [12]. Thus, now many of the devel-
oped and underdeveloped countries have shifted their research focus on the marine 
habitat and new marine-oriented projects are emerging worldwide. Majority of 
microbes belonging to class bacteria and fungi are now the target of biomedical 
study. The coastal bacterial samples that grow under saline conditions are a source 
of novel antibiotics, antitumor, and anti-inflammatory compounds [13]. The 
symbiotic microbial consortia have also been proven to be a rich source of bioactive 
compounds with pharmaceutical potential. Many bacteria and fungi have been 
sampled from the surfaces of marine plants and the internal tissues of invertebrates, 
and they have been found to be of increasing interest [14].
2.1 Marine bacteria
Marine bacteria are prolific producers of valuable secondary metabolites as 
they thrive in harsh oceanic climates. The marine isolate Pseudomonas, Gram-
negative, γ-proteo-bacteria is not well explored and only a limited number have 
been reported as producers of bioactive compounds. A bacterium strain KMM 
3042 that is aerobic, non-pigmented, produces some bioactive substances such as 
pyrroles, pseudopeptide pyrrolidinedione, phloroglucinol, phenazine, benzalde-
hyde, quinoline, quinolone, phenanthren, phthalate, andrimid, moiramides, zafrin, 
and bushrin [15]. Some of these bioactive compounds are antimicrobial agents, 
and dibutyl phthalate and di-(2-ethylhexyl) phthalate have been reported to be 
cathepsin-B inhibitors [16].
Stenotrophomonas strains isolated from sponge, sea urchin, and ophiura 
specimens showed remarkable antimicrobial and antifungal inhibitory activ-
ity. However, they showed negligible activity against Candida albicans, but 
these strains could substantially inhibit Gram-positive microorganisms. Though 
Stenotrophomonas maltophilia is an opportunistic pathogen, it also possesses biocon-
trolling capabilities [17]. Low molecular weight antimicrobial metabolites have also 
been reported from marine ark shell Anadara broughtoni associated heterotrophic 
bacteria (butanol extracts) that exhibit strong antimicrobial, hemolytic, and 
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surface activities [18]. Another recently discovered genus of bioactive substance 
producing marine bacteria is Pseudoalteromonas, the seawater species P. phenolica 
was reported to inhibit methicillin-resistant Staphylococcus aureus (MRSA) strains 
due to the presence of a brominated biphenyl compound, 3,3″,5,5″-tetrabromo-
2,2″-diphenyldiol [19]. Some strains of Pseudoalteromonas luteoviolacea have also 
been shown to inhibit the growth of protists [20]. Other marine invertebrates 
have also been shown to be a source of novel bioactive compound which was later 
identified as a tambjamine (4-methoxypyrrole-containing bioactive compounds) 
like alkaloid and re-designated as YP1 [21]. Pseudoalteromonas tunicate is associated 
with them and produces a yellow pigment that possesses antifungal activity [20, 
22]. These tambjamines are also known to possess antimicrobial, antitumorigenic, 
immunosuppressive, antiproliferative, and ichthyo-deterrent activities [20]. There 
are other evidences that points toward the colonizing bacteria present at the surface 
of higher organisms as the source of these compounds [23]. These studies have been 
further proven by Burke and colleagues by elucidation of YP1 biosynthetic pathway 
in Pseudoalteromonas tunicata [24].
2.2 Marine-derived fungi
Marine fungi have been known to produce a wide variety of bioactive metabo-
lites that possess anticancer, antibacterial, antiplasmodial, anti-inflammatory, and 
antiviral activity [25, 26]. This is due to the presence of some unique and exceptional 
carbon frameworks in them. These novel compounds are used as new lead structures 
for medicine and for plant protection. The detailed procedure for their isolation and 
cultivation from various marine organisms (sponges, algae, and mangrove plants) 
has been given by Kjer et al. [27]. They have also elucidated the structure of second-
ary metabolites produced by these fungi. A novel anthraquinone derivative with 
naphtho [1,2,3-de]chromene-2,7-dione skeleton was isolated from a marine filamen-
tous fungus, Aspergillus glaucus in the Fujian province of China and named asper-
giolide A [28]. It was found to exhibit cytotoxicity against K562 and P388 cell lines. 
Similarly, Penicillium sp., isolated from deep ocean sediment was found to exhibit 
antitumor activities in their alkaloid-rich extracts due to the presence of meleagrin 
D and E and roquefortine H and I. However, they exhibited weak cytotoxicity in 
comparison to the previously reported meleagrin B and meleagrin that functions by 
inducing HL-60 cell apoptosis and can also arrest the cell cycle through G2/M phase, 
respectively. The mode of action was the distinct substitutions on the imidazole ring 
that have a significant influence on the cytotoxicity of these alkaloids [29]. Some 
other novel compounds and metabolites were also isolated and characterized from 
marine fungi Ampelomyces sp. that possesses potent antimicrobial and antifouling 
compounds. The antilarvicidal effect was due to the presence of compound 3-chloro-
2,5-dihydroxybenzyl alcohol that effectively inhibited larval settlement of the 
tubeworm Hydroides elegans and of cyprids of the barnacle Balanus amphitrite. The 
compound is non-toxic and is also a potent antifoulant and/or antibiotic agent [30]. 
Another example of marine-derived fungus Cladosporium sp. also exhibited antibi-
otic and antifouling activity. It was later named as strain F14. The fungus produced 
the bioactive compounds in nutrient enriched cultivation media, in the presence of 
glucose or xylose [31]. Another study reported the marine-derived fungus Fusarium 
sp. (strain 05JANF165) to possess novel antimitotic and antifungal activity from its 
ethanol extracts. This compound was later identified and named as Fusarielin E [32].
Another marine-derived fungus of the genus Pseudallescheria was reported to 
produce a novel antibacterial dioxopiperazine, dehydroxybisdethiobis-methylthio-
gliotoxin from its broth. All three compounds exhibited potent antibacterial 
activity against the methicillin-resistant and multidrug-resistant Staphylococcus 
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aureus, whereas Gliotoxin showed a significant radical scavenging activity against 
1,1-diphenyl-2-picrylhydrazyl (DPPH) [33].
A marine isolate of the fungus Exophiala was also reported to exhibit a mild 
antibacterial activity against Staphylococcus aureus due to the presence of two novel 
antibacterial aspyrone derivatives, viz., Chlorohydroaspyrones A and B, and the 
previously described aspyrone, asperlactone, and penicillic acid from its broth [34].
Marine fungi also exhibited nematicidal effect along with antimicrobial activity. 
The same activity has also been reported from marine ascomycete Lachnum papyra-
ceum (Karst.) [35].
Another marine-derived Phoma herbarum strain was reported with significant 
radical scavenging activity against DPPH due to the presence of halogenated benzo-
quinones (bromochlorogentisylquinones A and B) [36].
2.3 Marine-derived actinomycetes
Actinomycetes are well-known to be the producers of secondary metabolites. 
Many well-known antibiotics, such as streptomycin, erythromycin, and tetracycline, 
with potent biological activities are produced by them [37]. Many marine-derived 
actinomycetes were found to be the producers of novel antitumor [38], antimalarial 
[39], and antimicrobial compounds [40, 41]. Another marine-derived actinomycete 
namely Nocardiopsis lucentensis produced four novel 3-methyl-4-ethylideneproline-
containing peptides called as Lucentamycins A-D from their fermentation broth [42]. 
Only compound Lucentamycins A and B exhibited strong in vitro cytotoxicity against 
HCT-116 human colon carcinoma [42]. In a similar study, marine-derived isolate of 
Streptomyces sp. were found to produce four new derivatives, Mansouramycin A-D, 
and the known 3-methyl-7-(methylamino)-5,8-isoquinolinedione from their ethyl 
acetate extract. These bioactive compounds, exhibited strong cytotoxicity with great 
degree of selectivity for non-small cell lung cancer, breast cancer, melanoma, and 
prostate cancer cells [43] suggesting their potential as anticancer drugs. Similarly, 
Perez and coworkers [44] isolated a macrodiolide Tartrolon D from the fermenta-
tion broths of Streptomyces sp. MDG-04-17-069. The isolated tartrolon was found 
to exhibit strong cytotoxic activity against three human tumor cell lines, viz., lung 
(A549), colon (HT29), and breast (MDA-MB-231) [44]. In yet another study, the 
secondary metabolites of a marine Saccharomonospora sp. yielded a novel alkaloid 
Lodopyridone, was found to be cytotoxic to HCT-116 human colon cancer cells [45].
Besides their antitumor and anticancerous potential, marine actinomycetes 
are also known for their antimicrobial activities also. A marine actinomycete, 
Marinispora was used to isolate a series of chlorinated bisindole pyrroles, 
Lynamicins A–E that exhibited a broad-spectrum antimicrobial activity against 
both the groups of Gram-positive and Gram-negative bacteria. These compounds 
were also effective against important drug-resistant pathogens, such as methicillin-
resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus 
faecium [41]. In a similar study, Carlson et al. [46] isolated the two novel bioactive 
compounds namely dienoyl tetramic acids tirandamycin C and D from the marine 
environmental isolate Streptomyces sp. These compounds were effective against 
vancomycin-resistant Enterococcus faecalis and are structurally similar to the previ-
ously identified compounds Tirandamycins A and B with a slight variation in the 
pattern of pendant oxygenation on the bicyclic ketal system.
Similarly, ethyl acetate extract of Streptomyces sp. isolate B8652 was used to isolate 
Trioxacarcins A, B, and C along with three new derivatives designated as Trioxacarcins 
D, E, and F [47]. These types of trioxacarcins exhibited good antimicrobial, antitumor, 
and antimalarial activity. Similarly, the crude extract of a marine Streptomyces strain 
that was isolated from deep sea sediments, exhibited potent antifouling activity [48].
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In yet another study, a marine-derived Actinomyces strain (NPS554) that was iso-
lated from Japan yielded two trialkyl-substituted aromatic acids, Lorneic acid A and 
B. It was observed that Lorneic acid-A had significant inhibition activity against 
phosphodiesterase (PDE)5 [49]. PDE5 inhibitors are of great pharmacological 
importance as they are used in erectile dysfunctions and pulmonary hypertension.
2.4 Marine-derived microalgae
Cyanobacteria are a diverse group of Gram-Negative bacteria, also known as 
blue-green algae that produce an array of secondary metabolites with antifungal, 
antiviral, antibiotic, and other properties. They also exhibit selective bioactivity 
against vertebrates, invertebrates, plants, microalgae, fungi, bacteria, viruses, and 
cell lines [50]. Thus, they are of great pharmaceutical value. Besides, there are other 
anticancer compounds, which were initially thought to be obtained from marine 
sources, are now known to be produced by cyanobacteria [51]. Ulithiacyclamide 
and Patellamide A belong to Cyanobactins, produced by cyanobacteria; possess 
potent antimalarial, antitumor, and multidrug reversing activities [52].
Some other examples of marine cyanobacterial bioactive natural products are 
viridamides A and B. It was observed that Viridamide A produced by a blackish-
green, mat-forming, filamentous cyanobacterium Oscillatoria nigroviridis showed 
antitrypanosomal, and antileishmanial activity [53]. In yet another study, the 
crude extracts of four green marine algae (Cladophora rupestris, Codium fragile sp. 
tomentosoides, Ulva intestinalis, and Ulva lactuca) were found to exhibit antiproto-
zoal activity [54]. All the algal extracts were active against T. brucei rhodesiense, and 
exhibited potent leishmanicidal activity [54]. This study was reportedly the first 
study to show antiprotozoal activity of British marine algae. Further, Desbois et al. 
[55] isolated an antibacterial polyunsaturated fatty acid, eicosapentaenoic acid 
(EPA) from the marine diatom, Phaeodactylum tricornutum Bohlin, which showed 
activity against a range of both Gram-positive and Gram-negative bacteria, includ-
ing methicillin-resistant Staphylococcus aureus (MRSA) [55].
Both micro- and macroalgae are used as nutraceuticals. Studies have shown that 
microalgae are rich sources of all the vital nutrients such as beta-carotene, vitamins 
C, A, E, H, B1, B2, B6, and B12, astaxanthin, polysaccharides, and polyunsaturated 
fatty acids [9]. Thus, their bioactive molecules are produced commercially for use as 
food additives, infant milk formulations, and dietary supplements [10].
Macroalgae, are also commonly known as seaweeds. They are the most popular 
type of algae in the nutraceutical industry and are used in a great variety of food 
and food ingredients, especially in Asian countries like Korea, Japan, and China. 
Macroalgae are also well-known for the production of agarose. They are also an 
important source of many bioactive metabolites and natural products that possess 
many nutritional and therapeutic functions. Some of the examples of bioactive 
constituents are proteins, furanone, polyunsaturated fatty acids (PUFA), L-α kainic 
acid, phenotics, pigments, phlorotannins, phyco-colloids (carrageenan and agar), 
and minerals. Likewise, red and brown seaweeds are also good sources of many 
vitamins, minerals, proteins, and essential fatty acids [56, 57]. They are also used 
to prepare bioactive peptides and to improve protein digestibility. Further, antihy-
pertensive bioactive peptides have also been isolated that can act as angiotensin-
converting enzyme (ACE) inhibitors [58].
2.5 Symbiotic interaction between marine microbes
Symbiosis is the mutual association between any two organisms for their mutual 
benefit that can be in terms of their nutritional needs or protection from prey. 
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Research studies have shown that a variety of secondary metabolites are produced 
as a result of this association especially obtained from algae and invertebrates. Their 
associated microbes perform various biological activities [59]. Some of the various 
marine fungi isolated are Haliclona simulans, Agaricomycotina, Mucoromycotina, 
Saccharomycotina, and Pezizomycotina [60]. A variety of media were used for their 
isolation and identification and their antimicrobial activities were also determined. 
Some of these isolates exhibited antimicrobial activity against Escherichia coli, 
Bacillus sp., Staphylococcus aureus, and Candida glabrata [60]. It has been found 
that sponge-microbial association is a potential chemical and ecological phenom-
enon that can serve as a sustainable resource for generating novel pharmaceutical 
leads. Thus, sponge microsymbionts are an important focus nowadays [61, 62]. In 
yet another study, a marine-derived fungal strain named M-3 was isolated from 
marine red alga Porphyra yezoensis. It was assessed for its antifungal activity against 
Pyricularia oryzae [63]. As a result, a novel compound diketopiperazine was isolated 
from the culture extracts and its structure was also elucidated by spectroscopic 
methods.
In another study, the butanol extracts of algal associated species 
Pseudoalteromonas issachenkonii were reported to show hemolysis and inhibition of 
Candida albicans. Their ethyl acetate extracts were also subjected to spectroscopic 
studies and revealed the presence of indole-2,3-dione, a type of isatin that was 
responsible for its antifungal activity [63]. In another study, a red-brown hemolytic 
pigment was also discovered [64]. Coral reefs widely prevalent in oceans are also 
unexplored source of novel bioactive compounds [65].
In another study, a marine gorgonian associated bacterium Bacillus amyloliq-
uefaciens was isolated from the South China Sea gorgonian, Junceella juncea. The 
studies showed their antibacterial against Escherichia coli, Bacillus subtilis, and 
Staphyloccocus aureus and antilarval properties against the larvae of bryozoan Bugula 
neritina. In yet another study, an antimicrobial activity of about 42 marine bacterial 
strains belonging to genera Alteromonas, Pseudomonas, Bacillus, and Flavobacterium 
was reported [66]. Besides this, certain mycoparasitic and fungicolous fungi were 
also shown to colonize other fungal physiological structures and were known 
to produce various bioactive agents [67]. In a study, five new natural products, 
Phomadecalins A, B, C, D, and Phomapentenone A, were reported from cultures of 
Phoma sp., a mitosporic fungal colonist isolated from the stromata of Hypoxylon sp. 
These bioactive compounds were found to be active against Gram-positive bacteria, 
Bacillus subtilis (ATCC 6051) and Staphylococcus aureus (ATCC 29213) [68].
3. Classification of marine nutraceuticals on the basis of chemical nature
Marine nutraceuticals can be broadly classified into Marine lipids (microalgal 
origin), polysaccharides derived from macro algae, marine probiotics, marine 
natural pigments, chitin and other related products, bioactive marine peptides/
enzymes, and vitamins.
3.1 Lipids
Lipids derived from marine microalgae are used in larval nutrition of aquacul-
ture, especially for enrichment of live feeds. Their other biological properties are 
anti-inflammatory, antiallergic, antiviral, and therapeutic. The wide spectrum of the 
properties is due to the presence of various components like polyunsaturated fatty 
acids (PUFA), highly unsaturated fatty acids (HUFA), and other substances. Various 
microalgal originated lipid/fatty acids and their activities [69] are given in Table 1.
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3.2 Polysaccharides
Generally, bacterial capsules contain polysaccharides. They form one of the 
important classes of secondary metabolites that are also important from pharmaceu-
tical point of view. Research studies have shown that these exopolysaccharides (EPS) 
particularly from marine bacteria can be used in various pharmaceutical and food 
processing agents. They can also be used in industries as thickeners, coagulating 
agents, adhesive agents, stabilizers, and as gelling agents. The exopolysaccharides 
possess good viscosity and pseudo-plastic properties that impart them ability to 
resist extremes of temperature, pH, and salinity. This increases their potential to be 
used as an industry friendly resource [70]. In a study, exopolysaccharides have been 
shown to possess immunomodulatory and antiviral properties on immunocompe-
tent cells in a marine bacteria Geobacillus thermodenitrificans that was isolated from a 
shallow marine vent of Volcano Island (Italy). This bacterium not only produced sec-
ondary metabolites against other organisms, but also produced certain compounds 
which help in bioremediation [71]. Certain other marine bacterial species are known 
as prolific producers of biosurfactants, bioemulsifiers, and exopolysaccharides.
Some polysaccharides are also derived from macroalgae. Seaweeds contain 
higher amounts of the polysaccharides like agar, alginates, and carrageenan. These 
act as food fiber and are collectively called phyco-colloids or hydrocolloids. Being 
rich in fiber, seaweeds exhibit health benefits like reducing the absorption of 
toxins, anticarcinogenic, and antioxidant properties. Example of the few important 
bioactive polysaccharides isolated from macroalgae (seaweeds) that possess the 
potential to be used as nutraceuticals are Fucoidan, Sphinganine amide, and caul-
erpicin (green algae), Carrageenan, Alginic acid and xylofucans, Hyperoxaluria, 
Sulfated polysaccharides, and Alginates. All these compounds possess wide range 
of biological properties such as antioxidant, antiangiogenic, antibacterial, antiviral 
and antitumor activities anticoagulant, immuno-modulating, hypolipidemic, and 
anti-inflammatory [72]. In addition to the phyco-colloids, seaweeds are sources 
of biologically active phytochemicals like carotenoids, phycobilins, fatty acids, 
vitamins, sterols, tocopherol, phycocyanins, and others.
Macroalgae are also rich sources of insoluble and soluble dietary fiber. They con-
tain chiefly indigestible sulfated polysaccharides. Some of the notable examples of 
structural and storage polysaccharides are fucan, agar, laminaran, carrageenan, and 
alginates that are found both in red and brown seaweeds. The alginates obtained 
from brown seaweeds are used as hydrocolloids and fucans from brown seaweeds 
are used in both food and cosmetics industries [73].
Microalgal lipid/fatty acid Biological action/function
Eicosapentaenoic acid (EPA) Nutraceutical; antimicrobial and anti-inflammatory
Gamma-linolenic acid (GLA) Integrity of tissue and delay of aging
Arachidonic acid (ARA) Aggregative and vasoconstrictive of platelets
Docosahexaenoic acid (DHA) Nutraceutical and brain development
Brassicasterol and stingmasterol Hypercholesterolemic
Gamma-amino-butyric acid 
(GABA)
Neuro-transmitter, antioxidant and anti-inflammatory
Okadaic acid Antifungal and promotion of the secretion of nerve growth factor 
(NGF)
Microcolin-A Immunosuppressive
Table 1. 
Microalgal lipid/fatty acids and their activity.
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A research highlighted the role of marine bacteria Bacillus circulans in the 
biodegradation of anthracene (a polyaromatic hydrocarbon) [74]. The said bacteria 
also produced a novel type of biosurfactant that exhibited excellent emulsification 
properties. It was shown that Bacillus circulans utilized anthracene as a sole carbon 
source for the production of biosurfactant. The researchers also reported the pro-
duction of another biosurfactant by an unnamed marine bacteria that has the ability 
to remove metal from solutions [75].
3.3 Bryostatins: bryozoan origin
The marine bryozoan, Bugula neritina, is the sole source of the bryostatins, a 
family of macrocyclic lactones with anticancer activity. Bryostatins are actually the 
bacterial products as B. neritina harbors the uncultivated gamma proteobacterial 
symbiont Candidatus Endobugula sertula. The clinical studies of bryostatins are also 
under going to study their potential for the treatment of leukemias, lymphomas, 
melanomas, and solid tumors [76]. Their mode of action is that they act through 
protein kinase C signal transduction to alter cellular activity.
3.4 Probiotics: marine lactic acid bacteria (LAB) origin
Microbial diversity of marine environments is very rich and can be helpful to 
develop safe and effective probiotics. Novel marine probiotics can be an effective 
alternative for fighting the antibiotic resistance. Lactobacillus and Bifidobacterium 
are found to possess antimutagenic [77] and immunomodulatory [78] activity 
in host animal. Different strains of marine probiotic bacteria are Lactobacillus 
(L. casei, L. acidophilus, L. rhamnosus GG (ATCC 53013), L. johnsonii La-1), 
Bifidobacterium (B. bifidum, B. longum, B. infantis, B. breve, B. adolescentis), 
Leuconostoc spp. (Ln. lactis, Ln. mesenteroides subsp. cremoris, Ln. mesenteroides subsp. 
dextranicum), and Streptococcus spp. (S. salivarius subsp. thermophiles).
The problem posed during the development of new marine probiotics is the 
isolation and identification of potential strain. Application of biotechnological and 
molecular biological tactics is necessary for the development of marine probiotic 
strains for use of aquatic industry [72].
3.5 Pigments: marine algae
Besides polysaccharides and lipids, marine macro- and microalgae also provide 
various types of the bioactive natural pigments. The natural pigments of the marine 
algae provide food by photosynthesis and also provide the pigmentation. In addition 
to these, the natural pigments are also found to exhibit health benefits which make 
them one of the important marine nutraceuticals. Chlorophyll-a, Lutein, zeaxan-
thin, and canthaxanthin possess antimutagenic properties; pheophytin-a exhibits 
neuroprotective, and anti-inflammatory action; Chlorophyll-a, Pheophorbide-a, 
Pyropheophytin-a, Phycoerythrobilin, Lutein, Fucoxanthin, Phycocyanin, 
Astaxanthin, Zeaxanthin, and Canthaxanthin are all good antioxidants. Alpha-
Carotene is also used as a food additive [72].
3.6 Chitosan: chitin
Chitosan is a natural polymer derived from chitin and it is the second most 
abundant polysaccharide after cellulose. Chitin is recovered from processing dis-
cards of shrimp, crab, lobster, and crayfish following de-proteinization and demin-
eralization. The chitin so obtained may then be deacetylated to afford chitosan. 
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Fungal cell walls are also rich in chitin. Chitin and chitosan are used as biomaterials 
in a variety of application in edible film industry, additives, for improving nutri-
tional quality, recovery of solid materials from food processing waste, in purifica-
tion of water, etc. The other biological properties of chitosan are antioxidant, 
hypocholesterolemic, antimicrobial, and anti-inflammatory activities [79].
Chitosan disrupts the barrier properties of the outer membrane of Gram-
negative bacteria due to ionic interaction between the cationic groups of the 
chitosan molecules and the anionic groups of the microbial cell membrane, which 
can rupture the cell membrane. Chitosan can also function as an antifungal agent 
by forming gas-permeable coats, interference with fungal growth and stimulation 
of various defense processes like, build-up of chitinases, production of proteinase 
inhibitors, and stimulators of callous synthesis.
The antioxidant property could be attributed to the ability of chitosan to 
chelate metals and combine with lipids. Derivatives of chitosan, namely, N,O-
carboxymethyl chitosan, N,O-carboxymethyl chitosan lactate, N,O-carboxymethyl 
chitosan acetate, and N,O-carboxymethyl chitosan pyrrolidine carboxylate had 
also exhibited the antioxidant activity. Chitosan possesses special properties for 
use in pharmaceutical, biomedical, food industry, health, and agriculture due to its 
biocompatibility, biodegradability, and non-toxic nature. Through encapsulation, 
it is being used as a vehicle for nutraceutical compounds and pharmacological com-
pounds. Chitosan derivatives may also be produced in order to obtain more effective 
products for certain applications [72].
3.7 Bioactive peptides/enzymes: marine origin
Peptides refer to the specific protein fragments that exhibit a specific biologi-
cal activity. Some of the peptides may exhibit multifunctional properties like 
opioid, immunomodulatory, antibacterial, antithrombotic, and antihypertensive 
activity. Biofunctional peptides have a size range of 2–20 amino acid residues and 
are encrypted within the sequence of the parent protein and are released during 
processing. They can be formed either by acid or alkaline hydrolysis. The major 
bioactivities of peptides are antihypertensive (ACE inhibitory), antioxidant, 
antimicrobial, antihypoallergenic activity, and cell immunity [80].
Proteins isolated from bacteria such as Dunaliella, Phaeodactylum tricornutum, 
and Arthrospira platensis possess potent antioxidant and anti-inflammatory activ-
ity which can be effectively used in aquaculture practices. Similarly, enzymes 
such as superoxide dismutase and carbonic anhydrase derived from Porphyridium, 
Anabaena, Isochrysis galbana, and Amphidinium carterae play an important role in 
regulating the metabolite waste (CO2).
3.8 Vitamins: marine microalgal origin
Marine microalgae are also known to have good amount of alpha-carotene. 
Microalgae like, Arthrospira, Isochrysis galbana, Porphyridium cruentum, and 
Tetraselmis are rich in vitamin C, K, A, E, and alpha-carotene which possess strong 
antioxidant activity. Vitamins A specially provitamin-A or alpha-carotene and vita-
min E or alpha-tocopherol function as source of strong antioxidant compounds and 
protect the cells from free radical damage by quenching these free radicals. Vitamin 
E, together with vitamin C and alpha-carotene, helps in improving antioxidant 
defenses in the body. Fat soluble vitamin K isolated from Pavlova helps in blood clot-
ting or coagulation. The role of antioxidant vitamins in health and disease control 
has been well documented [73]. Some of the important marine microorganisms, 
their bioactive metabolites and biological activity are highlighted in Table 2 [20].
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4.  Classical examples of some marine microflora and their nutraceutical 
potential
The oceans harbor one of the most diverse flora and fauna on our earth surface. Its 
biodiversity serves as an inexhaustible source of variety of biologically active com-
pounds such as antibiotic, antimicrobial, anti-inflammatory, anticancer, antioxidant, 
antimicrotubule, cytotoxic, photo-protective, and antifouling properties. A variety 
of novel range of microorganisms, such as bacteria (both free living and symbiotic), 
fungi, actinomycetes, microalgae-cyanobacteria, and diatoms, are found in the marine 
environment that are potent producers of important therapeutic compounds. They 
have also been found effective against many deadly infectious diseases such as AIDS, 
drug-resistant bacteria, including conditions of multiple bacterial infections. Only little 
research has been done on the biophysical and biochemical properties, their chemical 
structures and biotechnological applications of these marine bioactive substances, 
and their potential utilization in both cosmeceuticals and nutraceuticals. Some of the 
research studies on bioactive molecules from marine sources are discussed below.
Seaweeds provide a rich source of bioactive molecules. In this study, the anti-
microbial potential of Red sea weed, Gracilaria opuntia was investigated against 
Microorganism Marine microbial 
metabolites
Biological activity
Cyanobacteria Dolastatin-10 Antimicrotubule; and the synthetic analog, TZT-1027, 
as antitumor
Dolastatin-15 Antimicrotubule; and the synthetic analog, ILX-651, 
as antitumor
Curacin A Antimicrotubule
Toyocamycin Antifungal
Actinomycetes Resistoflavine Anticancerous and antibacterial
Marinomycin A Antitumor and antibiotic
Daryamide C Antitumor
Violacein Antiprotozoal
Bacteria Macrolactin S Antibacterial
Pyrone I and II Antibacterial
MC21-B Antibacterial
Fungi Meleagrin Antitumor
Oxaline Antitumor
Alternaramide Antibacterial
Algae Norharman Enzyme inhibitor
Calothrixin-A Antimalarial and anticancerous
Eicosapentanoic acid 
(EPA)
Treats heart disease, anti-inflammatory agent 
(rheumatoid arthritis and immunodeficiency 
diseases)
Symbiotic microbes Macrolactin V Antibacterial and antilarval
DAPG Antibacterial (anti-MRSA, anti-VRSA and anti-VRE)
BE-43472B Antibacterial (anti-MRSA and anti-VRE)
Table 2. 
Name and biological activity of some of the marine microbial metabolites.
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clinically important microorganism such as Escherichia coli, Staphylococcus aureus, 
Klebsiella pneumonia, and Pseudomonas putida that cause diseases in diabetic 
patients. Crude extracts prepared from aqueous, ethanol, and methanol extraction 
procedures revealed that aqueous extraction procedure have a wide range of anti-
microbial activity against all the test pathogens. The overall antibacterial activity 
assessed from the above results indicates the presence of active constituents in the 
extractions of seaweeds, which can be explored for the production of significant 
molecules that could be used in pharmaceutical industry [81].
In a similar another study on Gracilaria edulis, their phytochemical, antibacte-
rial, and antifungal activities of crude extracts were investigated. The methanol 
and aqueous extracts of Gracilaria edulis showed the presence of a number of 
metabolites such as alkaloids, saponin, phenols, terpenoids, proteins, flavonoids, 
glycosides, coumarins, and tannins. The red algae showed the significant antibacte-
rial activity against the clinical pathogens of Pseudomonas aeroginosa, Staphylococcus 
aureus, Bacillus cereus, Bacillus subtilis, Streptococcus pyogenes, Salmonella typhi as 
well as the fungus Aspergillus niger, Aspergillus flavus, Rhizopus indicus, and Candida 
albicans. The methanol extract showed the broader spectrum of antibacterial and 
antifungal activity when compared with aqueous extract [82].
In yet another study, the phytochemical and biological evaluation of some 
Sargassum species from Persian Gulf was also studied. These plants contain impor-
tant phytochemical constituents and have various potential biological activities. 
The study investigated the presence of phytochemical constituents and total 
phenolic quantity of the seaweeds Sargassum angustifolium, Sargassum oligocystum, 
and Sargassum boveanum. Cytotoxicity and antioxidant potential of these three 
Sargassum species was also analyzed. Sargassum angustifolium had the highest con-
tent of total phenolics and showed the highest antioxidant activity. Cytotoxic results 
showed that all species could inhibit cell growth effectively, for S. oligocystum, S. 
angustifolium, and S. boveanum, respectively. Thus considerable phytochemicals 
and moderate cytotoxic activity of S. angustifolium, S. oligocystum, and S. boveanum 
make them appropriate candidate for further studies and identification of their 
bioactive principles [83].
Further study on screening the algae for their phytochemicals from their 
extracts and testing on their antibacterial, antifungal and antioxidant potential 
was carried out. The algal strains were Tetraselmis sp., Dunaliella sp., Chlorella sp., 
Synechocystis sp., and Oscillatoria sp. Their extracts were prepared in an organic 
solvent and were used to screen for the presence of any phytochemicals. Later, their 
antimicrobial activity was also assessed against some selected bacterial and fungal 
species. Their antioxidant activity was also determined by DPPH scavenging assay 
and confirmed the presence of flavonoids in majority of the solvent extracts. In 
addition, the microalgal strains exhibited better antifungal activity as compared to 
bacterial. The solvent acetone from Dunaliella sp. showed highest antioxidant activ-
ity. The results showed the presence of Octadecanoic acid-4-hydroxy-methyl ester, 
benzoic acid, hexadecanoic acid, and Tetradecanoic acid, confirming the bioactive 
compounds in the algal extracts [84].
5. Other marine sources of nutraceuticals
Besides the microbes (which contributes around 19%), there are other 
marine flora and fauna, such as sponges (38%), coelenterates (23%), algae (10%), 
echinoderms (7%), tunicates (7%), mollusks (3%), and bryozoans (2%), have 
also shown to exhibit their potential to produce various therapeutic compounds 
13
Nutraceuticals from Microbes of Marine Sources
DOI: http://dx.doi.org/10.5772/intechopen.82369
including some novel anticancer substances. These compounds can also work 
against infectious diseases and inflammation [85].
6. Current market of nutraceuticals
Nutraceuticals, including functional foods and dietary supplements, have 
tremendous market potential. It has been estimated that the consumer demand of 
these health foods were around $250 billion only in 2014 alone and this figure is 
continue to rise and is expected to reach around $385 billion by 2020 [86].
Nutraceutical products are in demand throughout the world especially in 
developed countries, including United States of America (USA), Europe, Japan, 
Asia Pacific, Middle East, and Latin America. In particular, the global market is 
dominated by the United States of America, Europe, and Japan, which account 
for more than 85% of the market [87]. As per the Mintel survey carried out in the 
United Kingdom on vitamins and minerals supplements, it was observed that 25% 
of all adult populations were satisfied with the results of the nutraceutical products. 
The percentage of the usage varied according to the age of the consumers like the 
consumption of nutraceutical products was more common in elderly population as 
compared with the younger generation. There is a strong belief that in the com-
ing years, nutraceutical industry would remain at the forefront market including 
the Asian countries such as India and China. This is because of greater consumer 
awareness toward their health, increasing income levels and greater confidence in 
traditional and complimentary medicines [73].
The consumption of nutraceutical products in the USA is comparatively higher 
and accounts for approx. 40% of adults; in Spain, the nutraceuticals are consumed 
by the population aged between 35 and 80 years, and only around 9% consume 
dietary supplements as the source of vitamins and minerals. Besides, about 72% 
educated women that are of age between 35 and 49 years are more likely to choose 
nutraceuticals and dietary supplements [88].
In addition, the geriatric populations are also the most common consumers of 
these health supplements as they are more prone to micronutrient deficiencies. Due 
to the steady rise of geriatric population in developed countries, there is an urgent 
need to encourage and maintain a healthy lifespan and prevent chronic illnesses 
associated with aging [89].
Thus individuals with healthy lifestyles are more commonly the users of nutra-
ceutical products.
7. Conclusion
From the above discussion, it is quite pertinent to conclude that the marine 
environment harbors variety of microbial flora that have capability to produce a 
wide array of bioactive metabolites that can be used both in nutrition and pharma-
ceuticals to formulate new drugs that are effective against various drug-resistant 
pathogens. Though the saga of marine microbial bioactive metabolites is continuing 
with new compounds being added day by day, our knowledge is still a miniscule of 
what exists deep in the oceans. Interdisciplinary research and collaborative endeav-
ors are required amongst scientists, medical practitioners, marine microbiologists, 
and biotechnologists, to provide innovative approaches to marine based biomedical 
research. Thus, it is imperative to utilize our marine biodiversity and their bioac-
tive metabolites for discovering new therapeutic compounds of nutraceutical 
Nutraceuticals - Past, Present and Future
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importance. Recent biomedical tools, such as metabolomics and genetic engineer-
ing, can also be applied to increase their yield.
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